Patents by Inventor Stephan Thijssen
Stephan Thijssen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210241848Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.Type: ApplicationFiled: January 29, 2021Publication date: August 5, 2021Inventors: Xia Tao, Vaibhav Maheshwari, Peter Kotanko, Stephan Thijssen, Nadja Grobe
-
Publication number: 20210236705Abstract: methods, apparatuses, and systems for determining a peritoneal transport status of a patient based on mass analyzing low volumes of peritoneal dialysis (PD) effluent to generate patient information that may be evaluated using PD effluent fingerprints to determine peritoneal transport characteristics of the patient are described. For example, in one embodiment, a method of determining a transport status of a dialysis patient may include obtaining a volume of peritoneal dialysis (PD) effluent of the dialysis patient, generating patient information via mass analysis of the volume of PD effluent, and determining patient profile information based on evaluating the patient information with a profile library, the patient profile information comprising a peritoneal transport status classification. Other embodiments are described.Type: ApplicationFiled: January 29, 2021Publication date: August 5, 2021Inventors: Nadja Grobe, Peter Kotanko, Xia Tao, Stephan Thijssen
-
Publication number: 20210215666Abstract: An apparatus used in analyzing spent dialysate includes at least a first surface configured to accommodate a dialysate drain bag in a first predetermined position, and at least a second surface configured to accommodate a dialysate analysis device in a second predetermined position, such that when the dialysate drain bag is in the first predetermined position and the dialysate analysis device is in the second predetermined position, a light sensor of the dialysate analysis device is positioned to sense light passing through the dialysate drain bag.Type: ApplicationFiled: January 10, 2020Publication date: July 15, 2021Inventors: Peter Kotanko, Xia Tao, Mia G. Garbaccio, Stephan Thijssen, Nadja Grobe, Leticia M. Tapia Silva
-
Publication number: 20210138130Abstract: Techniques for vascular access identification and validation are disclosed. The techniques include: directly or indirectly acquiring an acquired value for a parameter that is a function of oxygen saturation (SO2) of a sample of blood in or obtained from a vascular access device (VAD) disposed in a subject; performing an evaluation of the acquired value at least by comparing the acquired value with one or more reference values; and responsive to the evaluation of the acquired value, assigning an identity classification to the VAD, wherein the identity classification is one of a central venous catheter (CVC), an arteriovenous access device (AVA), or another class of VAD.Type: ApplicationFiled: November 6, 2020Publication date: May 13, 2021Inventors: Peter Kotanko, Stephan Thijssen, Anna Meyring-Wösten, Hanjie Zhang
-
Publication number: 20210100945Abstract: Techniques and apparatus for de-priming processes are described. For example, in one embodiment, an apparatus may include at least one processor and a memory coupled to the at least one processor, the memory may include instructions that, when executed by the processor, may cause the at least one processor to determine a priming volume of a primer fluid infused into a priming system associated with the patient during a priming phase of the dialysis treatment, cause an ultrafiltration rate of an ultrafiltration pump of the dialysis machine in fluid communication with the patient to be changed from a treatment ultrafiltration rate to a de-priming ultrafiltration rate to remove the priming volume over a de-priming time period, and cause, after the de-priming time period, the ultrafiltration rate of the ultrafiltration pump to be changed back the treatment ultrafiltration rate. Other embodiments are described.Type: ApplicationFiled: October 2, 2020Publication date: April 8, 2021Inventors: Peter Kotanko, Stephan Thijssen
-
Publication number: 20200222618Abstract: Techniques and systems for determining an arteriovenous (AV) fistula maturation in a patient may include detecting a first series of oxygen saturation levels of the patient at a central venous catheter (CVC) associated with a first series of hemodialysis treatments prior to the AV fistula implantation are described. The AV fistula may then be implanted in the patient. A second series of oxygen saturation levels of the patient at the CVC associated with a second series of hemodialysis treatments may be detected. The second series of oxygen saturation levels may be compared to a stable threshold mature AV fistula oxygen saturation level. Among other determinations from the comparison, in response to one or more of the second series of oxygen saturation levels meeting or exceeding the stable threshold mature AV fistula oxygen saturation level, determining the AV fistula is mature. Other embodiments are described.Type: ApplicationFiled: January 16, 2019Publication date: July 16, 2020Inventors: Peter Kotanko, Stephan Thijssen, Hanjie Zhang, Israel Campos
-
Publication number: 20200139034Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: ApplicationFiled: January 8, 2020Publication date: May 7, 2020Inventors: Aurelio A. de los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Patent number: 10569000Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: GrantFiled: May 29, 2015Date of Patent: February 25, 2020Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Aurelio A. De los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Publication number: 20200030516Abstract: A system includes a device having a blood side, a solution side, and a semipermeable membrane structurally configured for diffusion of one or more solutes therethrough. The system also includes a first extracorporeal circuit having one or more first fluid connectors for connecting the blood side of the device to the vascular system of a first animal, a second extracorporeal circuit including one or more second fluid connectors for connecting the solution side of the device to the vascular system of a second animal, a first pump in fluid communication with at least one of the first and second extracorporeal circuits, and a driver mechanically coupled to the first pump, the driver configured to drive the first pump using energy from an energy source.Type: ApplicationFiled: October 1, 2019Publication date: January 30, 2020Inventors: Peter Kotanko, Stephan Thijssen
-
Patent number: 10525186Abstract: A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration.Type: GrantFiled: August 19, 2014Date of Patent: January 7, 2020Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Peter Kotanko, Stephan Thijssen, Nathan W. Levin
-
Publication number: 20190336670Abstract: A system includes a dialyzer having a blood side and a dialysate side, a first extracorporeal circuit including one or more first fluid connectors structurally configured to connect the blood side of the dialyzer to the vascular system of a kidney patient, and a second extracorporeal circuit including one or more second fluid connectors structurally configured to connect the dialysate side of the dialyzer to the vascular system of a healthy animal. The present teachings may thus include a system where hemodialysis is performed using a healthy animal (e.g., a person with normal kidney function) to help remove harmful solutes from, and provide helpful solutes to, a kidney patient. In this manner, the healthy animal is “virtually donating” its kidney function to the kidney patient.Type: ApplicationFiled: July 15, 2019Publication date: November 7, 2019Inventors: Peter Kotanko, Stephan Thijssen
-
Patent number: 10391220Abstract: A system includes a dialyzer having a blood side and a dialysate side, a first extracorporeal circuit including one or more first fluid connectors for connecting the blood side of the dialyzer to the vascular system of a kidney patient, a second extracorporeal circuit including one or more second fluid connectors for connecting the dialysate side of the dialyzer to the vascular system of a healthy animal, a first pump in fluid communication with at least one of the first and second extracorporeal circuits, and a driver mechanically coupled to the first pump, where the driver is configured to drive the first pump using energy from an energy source.Type: GrantFiled: January 12, 2018Date of Patent: August 27, 2019Assignee: FRESNIUS MEDICAL CARE HOLDINGS, INC.Inventors: Peter Kotanko, Stephan Thijssen
-
Publication number: 20190216996Abstract: A system includes a dialyzer having a blood side and a dialysate side, a first extracorporeal circuit including one or more first fluid connectors for connecting the blood side of the dialyzer to the vascular system of a kidney patient, a second extracorporeal circuit including one or more second fluid connectors for connecting the dialysate side of the dialyzer to the vascular system of a healthy animal, a first pump in fluid communication with at least one of the first and second extracorporeal circuits, and a driver mechanically coupled to the first pump, where the driver is configured to drive the first pump using energy from an energy source.Type: ApplicationFiled: January 12, 2018Publication date: July 18, 2019Inventors: Peter Kotanko, Stephan Thijssen
-
Patent number: 10319478Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen.Type: GrantFiled: September 7, 2012Date of Patent: June 11, 2019Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Doris Helene Fuertinger, Franz Kappel, Peter Kotanko, Nathan W. Levin, Stephan Thijssen
-
Publication number: 20190111200Abstract: Techniques and apparatuses for access recirculation of a patient during dialysis treatment are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to determine a first hemoglobin concentration for a dialysis system, determine a change in an ultrafiltration rate, determine a second hemoglobin concentration modified due to the change in the ultrafiltration rate based on a dialysis system model of the dialysis system, and determine an access recirculation value for the dialysis system. Other embodiments are described.Type: ApplicationFiled: October 16, 2018Publication date: April 18, 2019Inventors: Vaibhav Maheshwari, Peter Kotanko, Stephan Thijssen
-
Patent number: 10203321Abstract: The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's cliType: GrantFiled: December 1, 2011Date of Patent: February 12, 2019Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Peter Kotanko, Stephan Thijssen, Len Usvyat, Nathan W. Levin
-
Patent number: 9974491Abstract: A method of detecting an indication of a potential intradialytic morbid event (IME) by monitoring a patient's condition during excess fluid removal by ultrafiltration during a hemodialysis treatment includes determining the patient's relative blood volume (RBV), and removing a portion of the volume of excess fluid from blood of the patient at an initial ultrafiltration rate while periodically monitoring a second derivative over time of the relative blood volume (SDRBV). The method then includes continuing to remove excess fluid from blood of the patient at the same ultrafilration rate, or, optionally, incrementally increasing the ultrafiltration rate. The method further includes triggering an alarm for an IME for the patient if the SDRBV is in a range of between a low SDRBV alarm level and a high SDRBV alarm level, and, alternatively or additionally monitoring the patient's normalized blood pressure ratio, and taking a remedial action if the alarm is triggered.Type: GrantFiled: August 27, 2013Date of Patent: May 22, 2018Assignee: FRESENIUS MEDICAL CARE HOLDINGS, INC.Inventors: Fansan Zhu, Peter Kotanko, Stephan Thijssen, Nathan W. Levin
-
Patent number: 9883799Abstract: The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, including systolic blood pressure, serum albumin concentration level, body weight, body temperature, serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patiType: GrantFiled: December 2, 2010Date of Patent: February 6, 2018Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Peter Kotanko, Stephan Thijssen, Len Usvyat, Nathan W. Levin
-
Publication number: 20170239409Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: ApplicationFiled: May 29, 2015Publication date: August 24, 2017Inventors: Aurelio A. De los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Patent number: 9679111Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, the model including iron homeostasis, and employing the patient parameters and an initially selected ESA administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a hemodialysis system.Type: GrantFiled: November 5, 2013Date of Patent: June 13, 2017Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Doris Helene Fuertinger, Franz Kappel, Peter Kotanko, Nathan W. Levin, Stephan Thijssen